Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD40.Pan.CoV + Hiltonol
- Development stage
- Unknown
- Lead developer
- Vaccine Research Institute
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
CD40.Pan.CoV + Hiltonol is an investigational vaccine combination being developed as a booster for COVID-19. The vaccine component, CD40.Pan.CoV (also known as EDC.Pan.CoV), is a protein subunit vaccine consisting of a monoclonal antibody targeting the CD40 receptor on dendritic cells fused to SARS-CoV-2 antigens, including the Spike protein receptor-binding domain (RBD) and Nucleocapsid proteins. This design aims to direct antigens specifically to antigen-presenting cells to trigger a robust and broad immune response. Hiltonol (poly-ICLC), a synthetic double-stranded RNA and Toll-like receptor 3 (TLR3) agonist, is used as an adjuvant to enhance the vaccine's immunogenicity. The combination is currently being evaluated in Phase 1/2a clinical trials sponsored by ANRS Emerging Infectious Diseases and developed by the Vaccine Research Institute (VRI) and LinKinVax.
- Other names
- poly-ICLCCD40.Pan.CoV vaccine Hiltonol adjuvantedCD-40.Pan.CoV vaccine Hiltonol adjuvantedCD 40.Pan.CoV vaccine Hiltonol adjuvanted
02
Targets
CD40 (Cluster of differentiation 40 receptor)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on CD40.Pan.CoV + Hiltonol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD40.Pan.CoV + Hiltonol.